Array and Genentech expand oncology collaboration

Array BioPharma, from Boulder, CO, and US biotech giant Genentech, have expanded an agreement to develop small molecule drugs against an additional protein target in the field of oncology.

The original collaboration, which began in January 2004, was formed to advance two of Array's proprietary oncology programmes into clinical development. Under the expanded agreement, Array will receive additional research funding, as well as research and development milestone payments and product royalties based on the success of the new program.

'We believe Genentech's expansion of our research collaboration further validates Array's leadership position in cancer research,' said Robert Conway, chief executive officer, Array BioPharma. 'This collaboration leverages Array's proprietary small molecule drug discovery expertise with Genentech's cancer expertise, with the goal of creating products to address one the world's largest unmet medical needs and market opportunities.'

Under the terms of this expanded agreement, Genentech and Array will collaborate on the discovery of clinical candidates directed against a cancer target, generated by Genentech. Genentech will have the sole responsibility for clinical development and commercialisation of the resulting products.